Substantial advance supports that CMTM2 serve as an important performer in physiological and pathological processes. However, very little is clear about the relationship between CMTM2 and HBV-related disorders. Here, for the first time, we explore that whether or not serum CMTM2 is involved in HBV-related diseases. We found that CMTM2 values were significantly lower in patients compared to healthy control (p <0.001), using ELISA assay. Furthermore, serum CMTM2 levels were negatively correlated with HBV DNA levels in CHB patients but not correlated with the serum levels of ALT and AST. Serum CMTM2 concentrations were not correlated with the serum levels of ALT, AST and HBV DNA load in HBLC and HCC patients. In addition, analysis of the ROC curve indicated that CMTM2 levels were significantly associated with the diagnostic value of HBV-related disorders. Finally, downregulation of CMTM2 was observed in HBV-infected cell model. CMTM2 degradation could be attributed to HBx-activated Lys48 (K48)-linked polyubiquitination, which was abolished by treatment with the proteasome inhibitor MG132. HBV infection suppresses CMTM2 expression by activating ubiquitin-proteasome system. Serum CMTM2 levels can be adopted as an effective indicator of the pathogenesis of HBV-related disorders.

中文翻译：

---

鉴定血清 CMTM2 作为 HBV 相关疾病的潜在生物标志物

实质性进展支持 CMTM2 在生理和病理过程中发挥重要作用。然而，关于 CMTM2 与 HBV 相关疾病之间的关系知之甚少。在这里，我们首次探讨了血清 CMTM2 是否与 HBV 相关疾病有关。我们发现，与健康对照相比，患者的 CMTM2 值显着降低（p <0.001），使用 ELISA 测定。此外，血清 CMTM2 水平与 CHB 患者的 HBV DNA 水平呈负相关，但与血清 ALT 和 AST 水平无关。血清 CMTM2 浓度与 HBLC 和 HCC 患者的血清 ALT、AST 和 HBV DNA 载量水平无关。此外，ROC曲线分析表明CMTM2水平与HBV相关疾病的诊断价值显着相关。最后，在 HBV 感染的细胞模型中观察到 CMTM2 的下调。CMTM2 降解可归因于 HBx 激活的 Lys48 (K48) 连接的多泛素化，该泛素化通过蛋白酶体抑制剂 MG132 处理被消除。HBV感染通过激活泛素-蛋白酶体系统抑制CMTM2表达。血清CMTM2水平可作为HBV相关疾病发病机制的有效指标。HBV感染通过激活泛素-蛋白酶体系统抑制CMTM2表达。血清CMTM2水平可作为HBV相关疾病发病机制的有效指标。HBV感染通过激活泛素-蛋白酶体系统抑制CMTM2表达。血清CMTM2水平可作为HBV相关疾病发病机制的有效指标。